CEO Zhengbin (Bing) Yao was paid $9,374,153 in fiscal year 2025, ↑ up 289.5% from fiscal year 2024 (SEC filing 0001104659-26-050337 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$9,374,153 ↑ Zhengbin (Bing) Yao total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read ArriVent BioPharma's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper AVBP reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AVBP's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Zhengbin (Bing) Yao | $596,667 | $0 | $0 | $8,405,486 | $358,000 | $0 | $14,000 | $9,374,153 |
| Chief Executive Officer and President | ||||||||
| Stuart Lutzker | 515,779 | 0 | 0 | 2,654,364 | 247,574 | 0 | 14,000 | 3,431,717 |
| President, Research and Development | ||||||||
| Winston Kung | 492,417 | 0 | 0 | 2,654,364 | 246,287 | 0 | 14,000 | 3,407,068 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Zhengbin (Bing) Yao | $9,374,153 | $2,406,649 | — | ↑ +6,967,504 |
| Stuart Lutzker | 3,431,717 | 985,967 | — | ↑ +2,445,750 |
| Winston Kung | 3,407,068 | 1,832,573 | — | ↑ +1,574,495 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Stuart Lutzker | President | $3,431,717 |
| Winston Kung | CFO | $3,407,068 |
| Zhengbin (Bing) Yao | CEO | $9,374,153 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Merdad Parsey, M.D., Ph.D | Independent Director | $509,119 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Winston Kung | Option | 102,726 | 7.76 | — |
| Zhengbin (Bing) Yao | Option | 10,217 | 2.28 | — |
| Winston Kung | Option | 120,000 | 27.56 | — |
| Zhengbin (Bing) Yao | Option | 41,224 | 3.65 | — |
| Zhengbin (Bing) Yao | Option | 137,798 | 7.76 | — |
| Zhengbin (Bing) Yao | Option | 380,000 | 27.56 | — |
| Stuart Lutzker | Option | 2,820 | 2.28 | — |
| Stuart Lutzker | Option | 12,460 | 3.65 | — |
| Stuart Lutzker | Option | 25,680 | 7.76 | — |
| Stuart Lutzker | Option | 120,000 | 27.56 | — |
We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Merdad Parsey, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance | $39,375 | $0 | $469,744 | — | — | $509,119 |
| John Hohneker, M.DIndependent · Compensation · Nominating and Corporate Governance | 58,125 | — | 298,026 | — | — | 505,006 |
| Kristine PetersonIndependent · Lead Independent Director · Audit · Compensation (Chair) · Nominating and Corporate Governance | 86,250 | — | 298,026 | — | — | 395,820 |
| Chris W. NoletIndependent · Audit · Nominating and Corporate Governance | 68,750 | — | 298,026 | — | — | 343,525 |
| Zhengbin (Bing) Yao, Ph.DEmployee director · Board Chair · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Stuart Lutzker, M.D., Ph.DEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| James Healy, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance | — | — | — | — | — | — |
| Carl L. Gordon, Ph.D., CFAIndependent · Not standing for re-election · Departed during FY | — | — | — | — | — | — |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $235,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $252,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $252,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ArriVent BioPharma | 2025 | Zhengbin (Bing) Yao | $596,667 | $0 | $8,405,486 | $358,000 | $9,374,153 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Zhengbin (Bing) Yao | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Executive Compensation”. As printed: 9,374,153. Filing ↗machine: r1 · c35 · span 270607–270616 |
| 2 | Section 01, Stuart Lutzker | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Executive Compensation”. As printed: 3,431,717. Filing ↗machine: r3 · c35 · span 277875–277884 |
| 3 | Section 01, Winston Kung | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Executive Compensation”. As printed: 3,407,068. Filing ↗machine: r5 · c35 · span 285128–285137 |
| 4 | Section 08, Merdad Parsey, M.D., Ph.D | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 509,119. Filing ↗machine: span 390071–390078 |
| 5 | Section 08, John Hohneker, M.D | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 505,006. Filing ↗ |
| 6 | Section 08, Kristine Peterson | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 395,820. Filing ↗ |
| 7 | Section 08, Chris W. Nolet | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 343,525. Filing ↗ |
| 8 | Section 08, Zhengbin (Bing) Yao, Ph.D | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 08, Stuart Lutzker, M.D., Ph.D | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 08, James Healy, M.D., Ph.D | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 11 | Section 08, Carl L. Gordon, Ph.D., CFA | DEF 14A | 2026-04-28 | 0001104659-26-050337 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 252,500 + equity 0 + all other 0 = 252,500, summed across the director compensation table rows.machine: formula: Σ = 252,500 |
| 14 | ArriVent BioPharma (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050337 | CEO total compensation as printed in ArriVent BioPharma's own proxy. As printed: 9,374,153. Filing ↗machine: r1 · c35 · span 270607–270616 |